|
J B Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharma companies in India, has published its 2nd Sustainability (ESG) Report. The report reflects JB Pharma’s priorities in building sustainable, equitable and resilient systems to promulgate good health for the current and future generations.
The report is based on international reporting frameworks with reference to Global Reporting Initiative (GRI) 2021 standards & United Nations Sustainable Development Goals (UN SDGs).
JB Pharma reported 19% decrease in Green House Gases (GHG) intensity as compared to last year and commenced its journey of Scope 3 emissions accounting towards implementing systematic lowering of overall emissions.
This financial year also witnessed the completion of calculating scope 3 emissions for the first time for JB Pharma, where focus will be on total emissions across the organization and the external supply chain. The initiation of a renewable hybrid power supply (wind & solar) across all manufacturing facilities in India resulted in 8464.89 GJ energy being derived from these sources.
Nikhil Chopra, CEO & whole time director, JB Pharma at the launch of the report said, “ESG is an imperative for progressive businesses operating in a dynamic environment. The 2nd report highlights progress made and an action-oriented approach for the next financial year. It is prepared following the international reporting frameworks i.e. GRI as its core standard, and linkages with the United Nations Sustainable Development Goals (UN SDGs).”
“People, patients and the planet will always remain at the fulcrum of JB’s existence as we constantly evolve and embed responsible practices for a sustainable world. Underpinned by a growth- mindset, robust governance systems and state-of-the-art facilities, JB Pharma is committed towards providing quality and cost-effective medicines across the globe.” He added.
Nearly forty thousand litres of water was treated through Effluent Treatment Plants (ETP) and re-used with all manufacturing sites being zero liquid discharge. 93.6% of non-hazardous waste generated was diverted from disposal and there was 32.4% decrease in hazardous waste sent to landfills. Materiality assessments were revisited on the basis which key policies were developed which serve as a driving force for implementing best governance practices across the entire value chain.
As employees are the fulcrum of the organisation bringing goals to fruition, enhancing their holistic well- being is of paramount importance in JB Pharma. In line with organizational ethos, initiatives like JB Cares – a 360-degree in-house wellness app was introduced with the aim of amplifying employee physical and mental well-being. A continuous learning and development framework (I.D.E.A) with innovative leadership development, talent development and upskilling programmes at various levels of the workforce is underway to stimulate employees’ personal as well as organisational goals.
The organisation witnessed a 14.4% increase in women representation since 2019-20, with 14% increase in women representation across fields, historically dominated by their counterparts in the industry. Championing a culture of inclusion and belonging, JB Pharma has initiated drafting of a charter and framework for Diversity, Equity and Inclusion (DE&I) framework which helps in nurturing talent and creating equal opportunities in the organization.
With a people centric approach, JB Pharma’s CSR interventions continue to positively impact the lives of communities across the geographies.
J B Pharma, established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for the majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has 6 brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA.
|